925-P: Using Machine Learning to Predict Dynamic Cardiovascular Risks and Identify the Treatment Responses of Canagliflozin in Type 2 Diabetes Mellitus
Evaluating cardiovascular risks and choosing the right pharmacotherapy is crucial for
personalized treatment in patients with type 2 diabetes. Our study aims to dynamically …
personalized treatment in patients with type 2 diabetes. Our study aims to dynamically …
Phenomapping-derived tool to individualize the effect of canagliflozin on cardiovascular risk in type 2 diabetes
OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibitors have well-documented
cardioprotective effects but are underused, partly because of high cost. We aimed to develop …
cardioprotective effects but are underused, partly because of high cost. We aimed to develop …
Individualizing Cardiovascular Benefits of Canagliflozin Based on Multidimensional Computational Phenomaps of the CANVAS Trials
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have well-documented
cardioprotective effects in broad groups of patients with type 2 diabetes mellitus (T2DM) but …
cardioprotective effects in broad groups of patients with type 2 diabetes mellitus (T2DM) but …
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin …
X Zou, Q Huang, Y Luo, Q Ren, X Han, X Zhou, L Ji - Diabetologia, 2022 - Springer
Aims/hypothesis Data-driven diabetes subgroups have shown distinct clinical characteristics
and disease progression, although there is a lack of evidence that this information can guide …
and disease progression, although there is a lack of evidence that this information can guide …
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease …
Aims/hypothesis Type 2 diabetes mellitus can manifest over a broad clinical range, although
there is no clear consensus on the categorisation of disease complexity. We assessed the …
there is no clear consensus on the categorisation of disease complexity. We assessed the …
Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program
Rationale & Objective Canagliflozin reduces the risk for cardiovascular and kidney
outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of …
outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of …
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood
glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 …
glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 …
Bayesian network meta-analysis (NMa) to assess the relative efficacy of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with …
V Taieb, M Pacou, M Schroeder… - Value in …, 2015 - valueinhealthjournal.com
Objectives To assess the relative efficacy of canagliflozin, a sodium glucose co-transporter 2
inhibitor (SGLT2) as add-on to insulin+/-oral antihyperglycaemic drugs for the treatment of …
inhibitor (SGLT2) as add-on to insulin+/-oral antihyperglycaemic drugs for the treatment of …
Bayesian network Meta-Analysis (Nma) to Assess the relative Efficacy of Canagliflozin Monotherapy over 26 weeks In Patients with Type 2 Diabetes mellitus (T2dm)
M Schroeder, V Taieb, D Belhadi… - Value in …, 2015 - valueinhealthjournal.com
OBJECTIVES To inform a multiple technology appraisal to be conducted by the National
Institute for Health and Care Excellence on the use of agents that inhibit sodium-glucose co …
Institute for Health and Care Excellence on the use of agents that inhibit sodium-glucose co …
Effect of canagliflozin on heart failure hospitalization in diabetes according to baseline heart failure risk
Abstract Background In the CANVAS (Canagliflozin Cardiovascular Assessment Study)
program, canagliflozin reduced the risk of heart failure (HF) hospitalization among …
program, canagliflozin reduced the risk of heart failure (HF) hospitalization among …
相关搜索
- machine learning treatment responses
- diabetes mellitus cardiovascular risk
- diabetes mellitus treatment responses
- diabetes mellitus machine learning
- effect of canagliflozin cardiovascular risk
- canvas program cardiovascular risk
- machine learning high risk
- machine learning extremity amputation
- machine learning canagliflozin prescriptions
- diabetes mellitus relative efficacy
- diabetes mellitus bayesian network
- diabetes mellitus meta analysis
- diabetes mellitus canagliflozin in patients
- diabetes mellitus canvas program
- risk reductions outcomes with canagliflozin
- high risk diabetes patients